An international study recently published in the British academic journal “Nature Biotechnology” shows that a drug candidate discovered and designed by artificial intelligence to treat idiopathic pulmonary fibrosis may also have potential anti-aging effects. According to a paper jointly published by researchers from biomedical company Insilon Intelligence and Harvard Medical School in the US, the research team analyzed serum proteomics data collected from 42 patients with idiopathic pulmonary fibrosis during a 12-week clinical trial and found that some indicators related to aging in patients treated with the drug Rentosertib had improved, and the “aging clock” used to assess biological age could drop as much as 6 years.

An international study recently published in the British academic journal “Nature Biotechnology” shows that a drug candidate discovered and designed by artificial intelligence to treat idiopathic pulmonary fibrosis may also have potential anti-aging effects. According to a paper jointly published by researchers from biomedical company Insilon Intelligence and Harvard Medical School in the US, the research team analyzed serum proteomics data collected from 42 patients with idiopathic pulmonary fibrosis during a 12-week clinical trial and found that some indicators related to aging in patients treated with the drug Rentosertib had improved, and the “aging clock” used to assess biological age could drop as much as 6 years.